Factors Associated With Sub - Targeted Therapeutic Dose Of Renin - Angiotensin Blockage Among Chronic Heart Failure With Reduced Ejection Fraction Patients

Chulalongkorn University

Status: Completed

Conditions: Heart Failure With Reduced Ejection Fraction

Treatments: Drug: Renin-Angiotensin System Inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT06382571

026/66

Details and patient eligibility

About

Objective: To analyze factors associated with Thai heart failure with reduced ejection fraction patients who received sub-target doses of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs).

Methods: The retrospective cohort study was designed to collect data on Thai heart failure with reduced ejection fraction patients at Out-patient Clinic, Trat Hospital and Phrapokklao Hospital from January 2016 to December 2020. Thirteen factors were analyzed to determine their association with the sub-target group.

Enrollment: 396 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who were first diagnosed be heart failure with left ventricular ejection fraction less than 40%.
• Received one of ACEIs,ARBs,ARNI drugs.

Exclusion criteria

• Electronic medical records was not complete enough to analyse.
• Patients who had history of heart transplantation or had heart transplantation plan in last 12 months.

Trial design

396 participants in 2 patient groups

Sub - target dose group

Description:

Patients who received sub - target dose of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs).

Treatment:

Drug: Renin-Angiotensin System Inhibitor

Target dose group

Description:

Patients who received target dose or maximal tolerated dose of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs)

Treatment:

Drug: Renin-Angiotensin System Inhibitor